Immuneering Corp - Ordinary Shares Class A

NASDAQ:IMRX   3:59:51 PM EDT
4.43
-0.27 (-5.74%)
Other Pre-Announcement

Immuneering Reports First Quarter 2022 Financial Results And Recent Business Highlights

Published: 05/10/2022 10:42 GMT
Immuneering Corp - Ordinary Shares Class A (IMRX) - Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights.
Ind Filing for Imm-1-104 Expected in Q3 2022; Enrollment of First Patient Expected in Q4 2022.
Q1 Loss per Share $0.49.
Reiterates Full Year GAAP Operating Expenses to Be Between $55.0 Million and $60.0 Million.
Q1 Earnings per Share View $-0.45 -- Refinitiv Ibes Data (analyst estimates).
Qtrly Revenue $183,698 Versus $748,200.